The effects of grape seed extract supplementation on cardiovascular risk factors, liver enzymes and hepatic steatosis in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled study

Ghanbari P 1 , Raiesi D 2 , Alboebadi R 1 , Zarejavid A 3 , Dianati M 4 , Razmi H 5 Show all authors , Bazyar H 6

Affiliations 

  • 1 Student Research Committee, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
  • 2 Department of Internal Medicine, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
  • 3 Nutrition and Metabolic Diseases Research Center, Clinical Sciences Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
  • 4 School of Medical and Life Sciences, Sunway University, Sunway City, Malaysia
  • 5 Student Research Committee, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. [email protected]
  • 6 Department of Public Health, Sirjan School of Medical Sciences, Sirjan, Iran. [email protected]
BMC Complement Med Ther, 2024 May 16;24(1):192.
PMID: 38755622 DOI: 10.1186/s12906-024-04477-3

Abstract

BACKGROUND: Despite the high antioxidant potential of grape seed extract (GSE), very limited studies have investigated its effect on non-alcoholic fatty liver disease (NAFLD). Therefore, this study was conducted with the aim of investigating the effect of GSE on metabolic factors, blood pressure and steatosis severity in patients with NAFLD.

METHODS: In this double-blind randomized clinical trial study, 50 NAFLD patients were divided into two groups of 25 participants who were treated with 520 mg/day of GSE or the placebo group for 2 months. The parameters of glycemic, lipid profile, blood pressure and steatohepatitis were measured before and after the intervention.

RESULTS: The GSE group had an average age of 43.52 ± 8.12 years with 15 women and 10 men, while the placebo group had an average age of 44.88 ± 10.14 years with 11 women and 14 men. After 2 months of intervention with GSE, it was observed that insulin, HOMA-IR, TC, TG, LDL-c, ALT, AST, AST/ALT, SBP, DBP and MAP decreased and QUICKi and HDL-c increased significantly (p-value for all

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

MeSH terms
Similar publications